<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485406</url>
  </required_header>
  <id_info>
    <org_study_id>115373</org_study_id>
    <secondary_id>2011-002225-22</secondary_id>
    <nct_id>NCT01485406</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers</brief_title>
  <official_title>Safety and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine 2830930A When Administered as a Single Dose in Healthy Toddlers Aged 12-23 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the&#xD;
      GSK Biologicals' pneumococcal vaccine 2830930A in toddlers aged 12 to 23 months at study&#xD;
      entry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2011</start_date>
  <completion_date type="Actual">March 15, 2012</completion_date>
  <primary_completion_date type="Actual">March 15, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of each grade 3 solicited adverse event with relationship to vaccination</measure>
    <time_frame>Within 7 days (Day 0-Day 6) after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of grade 3 unsolicited adverse events with relationship to vaccination</measure>
    <time_frame>Within 31 days (Day 0-Day 30) after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events with relationship to vaccination</measure>
    <time_frame>During the entire study (from Month 0 up to Month 1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each solicited adverse event</measure>
    <time_frame>Within 7 days (Day 0-Day 6) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of each unsolicited adverse event</measure>
    <time_frame>Within 31 days (Day 0-Day 30) after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse event</measure>
    <time_frame>During the entire study (from Month 0 up to Month 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the immune responses to the components of the 2830930A vaccine</measure>
    <time_frame>One month post-vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Pn Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toddlers 12-23 months of age receiving GSK2830930A vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Toddlers 12-23 months of age receiving Synflorix.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal vaccine GSK2830930A</intervention_name>
    <description>1 dose administered intramuscularly</description>
    <arm_group_label>Pn Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorixâ„¢</intervention_name>
    <description>1 dose administered intramuscularly</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who the investigator believes that their parent(s)/Legally Acceptable&#xD;
             Representative(s) (LARs) can and will comply with the requirements of the protocol.&#xD;
&#xD;
          -  A male or female between, and including 12 to 23 months of age at the time of&#xD;
             vaccination.&#xD;
&#xD;
          -  Written informed consent obtained from the parents/LAR(s) of the subject.&#xD;
&#xD;
          -  Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          -  Born after a gestation period of at least 36 weeks.&#xD;
&#xD;
          -  Previously completed three-dose vaccination course with Synflorix.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child in care.&#xD;
&#xD;
          -  Use of any investigational or non-registered product other than the study vaccine(s)&#xD;
             within 30 days preceding the first dose of study vaccine, or planned use during the&#xD;
             study period.&#xD;
&#xD;
          -  Chronic administration of immunosuppressants or other immune-modifying drugs since&#xD;
             birth.&#xD;
&#xD;
          -  Planned administration/administration of a vaccine containing diphtheria- or tetanus-&#xD;
             toxoid or CRM197 and not foreseen by the study protocol during any time of the study&#xD;
             period, or of any other vaccines not foreseen by the protocol in the period starting&#xD;
             from 30 days before the vaccine dose and ending 30 days after, with the exception of&#xD;
             licensed influenza vaccines.&#xD;
&#xD;
               -  The licensed influenza vaccines are always allowed, even if concomitantly&#xD;
                  administered with the study vaccines but should be documented in the &quot;Concomitant&#xD;
                  vaccination&quot; of the electronic Case Report Form.&#xD;
&#xD;
          -  Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational product&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination&#xD;
&#xD;
          -  Family history of congenital or hereditary immunodeficiency.&#xD;
&#xD;
          -  History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the vaccine(s).&#xD;
&#xD;
          -  Major congenital defects or serious chronic illness, including Kawasaki's syndrome.&#xD;
&#xD;
          -  History of any neurological disorders or seizures, including conditions such as&#xD;
             hypotensive-hyporesponsive episodes, encephalopathy and any convulsions (afebrile and&#xD;
             febrile).&#xD;
&#xD;
          -  Acute disease and/or fever at the time of enrolment.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding vaccination or planned administration during study period.&#xD;
&#xD;
          -  Any medical condition which might interfere with the assessment of the study&#xD;
             objectives in the opinion of the investigator.&#xD;
&#xD;
          -  Previous receipt of a booster dose (fourth dose) of Synflorix.&#xD;
&#xD;
          -  Anaphylaxis following previous administration of vaccines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kehl</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berchtesgaden</city>
        <state>Bayern</state>
        <zip>83471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braunatal</city>
        <state>Hessen</state>
        <zip>34225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Horn M, Behre U, Traskine M, Dobbelaere K, Borys D. Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial. Hum Vaccin Immunother. 2021 May 4;17(5):1463-1469. doi: 10.1080/21645515.2020.1810493. Epub 2020 Nov 11.</citation>
    <PMID>33175600</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus influenzae</keyword>
  <keyword>Safety</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Toddlers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study is available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com/Posting.aspx?ID=20770</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

